Galera Therapeutics, Inc. (GRTX)

$1.54

+0.04 (+2.67%)
Rating:
Recommendation:
-
Symbol GRTX
Price $1.54
Beta 2.029
Volume Avg. 0.09M
Market Cap 41.305M
Shares () -
52 Week Range 1.12-8.51
1y Target Est -
DCF Unlevered GRTX DCF ->
DCF Levered GRTX LDCF ->
ROE 108.96% Strong Buy
ROA -113.68% Strong Sell
Operating Margin -
Debt / Equity -173.37% Sell
P/E -
P/B -0.50 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest GRTX news


Dr. J. Mel Sorensen
Healthcare
Biotechnology
NASDAQ Global Market

Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.